EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus

Catherine Chiron iD, Nicole Chemaly iD, Laurent Chancharme, Rima Nabbout iD

Developmental Medicine & Child Neurology · 2023

DOI: 10.1111/dmcn.15638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Developmental Medicine & Child Neurology, 2023. Verfasst von Catherine Chiron und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology and French Reference Center for Rare Epilepsies (CRéER), APHP, Necker-Enfants Malades Hospital, Paris, France. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Status Epilepticus. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the safety and efficacy of stiripentol initiated before 2 years of age in patients with Dravet syndrome.

Method

This was a 30‐year, real‐world retrospective study. We extracted the data of the 131 patients (59 females, 72 males) who initiated stiripentol before 2 years of age between 1991 and 2021 from the four longitudinal databases of Dravet syndrome available in France.

Results

Stiripentol was added to valproate and clobazam (93%) at 13 months and a median dose of 50 mg/kg/day. With short‐term therapy (30 minutes) disappeared in 55% of patients. With long‐term therapy (last visit on stiripentol

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicStatus EpilepticusInfantMaleFemaleHumansChild, PreschoolAnticonvulsantsRetrospective StudiesTreatment OutcomeSeizuresDioxolanes

Substanzen

AnticonvulsantsstiripentolDioxolanes

Autor:innen und Institutionen

  • Pediatric Neurology and French Reference Center for Rare Epilepsies (CRéER), APHP, Necker-Enfants Malades Hospital, Paris, France.
  • INSERM U1141 and Institut Neurospin, Paris, France.
  • Biocodex, Compiègne, France.
  • INSERM U1163, Institut Imagine, chaire GEEN-DS, Université Paris cité, Paris, France.

ORCID-Profile: Catherine Chiron, Nicole Chemaly, Rima Nabbout

Zitieren

APA

Chiron, C., Chemaly, N., Chancharme, L., & Nabbout, R. (2023). Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.15638

Vancouver

Chiron C, Chemaly N, Chancharme L, Nabbout R. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Developmental Medicine & Child Neurology. 2023. doi:10.1111/dmcn.15638

BibTeX
@article{Chiron2023,
  author = {Chiron, Catherine and Chemaly, Nicole and Chancharme, Laurent and Nabbout, Rima},
  title = {Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus},
  journal = {Developmental Medicine & Child Neurology},
  year = {2023},
  doi = {10.1111/dmcn.15638}
}
Kostenlos starten →